JPWO2020033791A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033791A5 JPWO2020033791A5 JP2021506632A JP2021506632A JPWO2020033791A5 JP WO2020033791 A5 JPWO2020033791 A5 JP WO2020033791A5 JP 2021506632 A JP2021506632 A JP 2021506632A JP 2021506632 A JP2021506632 A JP 2021506632A JP WO2020033791 A5 JPWO2020033791 A5 JP WO2020033791A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- increased
- nucleic acid
- macrophages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 111
- 210000004027 cells Anatomy 0.000 claims description 73
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 210000001185 Bone Marrow Anatomy 0.000 claims description 46
- 210000002540 Macrophages Anatomy 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 43
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 39
- 239000002924 silencing RNA Substances 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 29
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 27
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 26
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims description 26
- 102100005862 CCR2 Human genes 0.000 claims description 21
- 108060001122 CRTISO Proteins 0.000 claims description 21
- 230000002757 inflammatory Effects 0.000 claims description 21
- 210000001616 Monocytes Anatomy 0.000 claims description 20
- 125000002015 acyclic group Chemical group 0.000 claims description 20
- 125000004122 cyclic group Chemical group 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 238000006011 modification reaction Methods 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 101700063802 CSF1R Proteins 0.000 claims description 16
- 230000000692 anti-sense Effects 0.000 claims description 16
- 102100008191 CD8A Human genes 0.000 claims description 14
- 229920000972 Sense strand Polymers 0.000 claims description 14
- 102100005175 CSF1R Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 210000004322 M2 macrophage Anatomy 0.000 claims description 13
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 13
- 102100006400 CSF2 Human genes 0.000 claims description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 12
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims description 12
- 230000020411 cell activation Effects 0.000 claims description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 12
- 210000002443 helper T lymphocyte Anatomy 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 230000003042 antagnostic Effects 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 201000009030 carcinoma Diseases 0.000 claims description 10
- 230000003247 decreasing Effects 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940107161 Cholesterol Drugs 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 102100009326 CD163 Human genes 0.000 claims description 7
- 108010009992 CD163 antigen Proteins 0.000 claims description 7
- 102100019284 CD53 Human genes 0.000 claims description 7
- 101700029492 CD53 Proteins 0.000 claims description 7
- 102100019451 CD80 Human genes 0.000 claims description 7
- 101700080477 CD80 Proteins 0.000 claims description 7
- 102100009641 CXCL10 Human genes 0.000 claims description 7
- 101710032181 CXCL10 Proteins 0.000 claims description 7
- 102100009686 CXCL9 Human genes 0.000 claims description 7
- 101700052645 CXCL9 Proteins 0.000 claims description 7
- 210000001787 Dendrites Anatomy 0.000 claims description 7
- 102100015541 FCGR3A Human genes 0.000 claims description 7
- 101710044656 FCGR3A Proteins 0.000 claims description 7
- 101710044657 FCGR3B Proteins 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 102000003810 Interleukin-18 Human genes 0.000 claims description 7
- 108090000171 Interleukin-18 Proteins 0.000 claims description 7
- 102100004732 MRC1 Human genes 0.000 claims description 7
- 101700029479 MRC1 Proteins 0.000 claims description 7
- 210000004693 NK cell Anatomy 0.000 claims description 7
- 210000000440 Neutrophils Anatomy 0.000 claims description 7
- 102100014586 SELPLG Human genes 0.000 claims description 7
- 101710023851 SELPLG Proteins 0.000 claims description 7
- 102100017077 VSIG4 Human genes 0.000 claims description 7
- 101700055320 VSIG4 Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 102000038129 antigens Human genes 0.000 claims description 7
- 108091007172 antigens Proteins 0.000 claims description 7
- 238000000386 microscopy Methods 0.000 claims description 7
- 230000000051 modifying Effects 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 210000000481 Breast Anatomy 0.000 claims description 6
- 206010073251 Clear cell renal cell carcinoma Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000001747 exhibiting Effects 0.000 claims description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 6
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 102100005176 CSF1 Human genes 0.000 claims description 5
- 108060001954 CSF1 Proteins 0.000 claims description 5
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims description 5
- 230000003308 immunostimulating Effects 0.000 claims description 5
- 102100007290 CD274 Human genes 0.000 claims description 4
- 101710012053 CD274 Proteins 0.000 claims description 4
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims description 4
- 102100005310 CTLA4 Human genes 0.000 claims description 4
- 101700054183 CTLA4 Proteins 0.000 claims description 4
- 102000013264 Interleukin-23 Human genes 0.000 claims description 4
- 108010065637 Interleukin-23 Proteins 0.000 claims description 4
- 102100007289 PDCD1LG2 Human genes 0.000 claims description 4
- 101710011976 PDCD1LG2 Proteins 0.000 claims description 4
- 102100013504 RPL17 Human genes 0.000 claims description 4
- 108060007796 SPATA2 Proteins 0.000 claims description 4
- 230000001472 cytotoxic Effects 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000009956 Adenocarcinoma Diseases 0.000 claims description 3
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 3
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 210000004556 Brain Anatomy 0.000 claims description 3
- 208000002445 Cystadenocarcinoma Diseases 0.000 claims description 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 208000005017 Glioblastoma Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims description 3
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 210000003734 Kidney Anatomy 0.000 claims description 3
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 3
- 210000004185 Liver Anatomy 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000007312 Paraganglioma Diseases 0.000 claims description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 3
- 206010034674 Peritonitis Diseases 0.000 claims description 3
- 206010034800 Phaeochromocytoma Diseases 0.000 claims description 3
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000002918 Testicular Germ Cell Tumor Diseases 0.000 claims description 3
- 208000008732 Thymoma Diseases 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 3
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 3
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 3
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 201000010915 glioblastoma multiforme Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 3
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 3
- 230000000268 renotropic Effects 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 210000001519 tissues Anatomy 0.000 claims description 3
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims description 3
- 201000005969 uveal melanoma Diseases 0.000 claims description 3
- 229960005486 vaccines Drugs 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002147 killing Effects 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000002062 proliferating Effects 0.000 claims description 2
- 230000002829 reduced Effects 0.000 claims description 2
- 230000001235 sensitizing Effects 0.000 claims description 2
- 231100000202 sensitizing Toxicity 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 102100009534 TNF Human genes 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
Description
一実施形態では、少なくとも1つの組成物と接触した骨髄由来細胞は、以下:a)単球及び/またはマクロファージによるCCR2及び/またはCSF1R受容体の減少した発現、b)単球及び/またはマクロファージによる表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、c)単球及び/またはマクロファージによるCD206、CD163、CD16、CD53、VSIG4、PSGL-1、TGFb、及び/またはIL-10の減少した発現、d)単球及び/またはマクロファージによるIL-1β、TNF-α、IL-12、IL-18、GM-CSF、CCL3、CCL4、及びIL-2からなる群から選択される少なくとも1つのサイトカインもしくはケモカインの増加した分泌、e)単球及び/またはマクロファージによるIL-10の発現に対するIL-1β、IL-6、及び/またはTNF-αの発現の増加した比率、f)増加したCD8+細胞傷害性T細胞活性化、g)CD8+細胞傷害性T細胞活性化の増加した動員、h)増加したCD4+ヘルパーT細胞活性、i)CD4+ヘルパーT細胞活性の増加した動員、j)増加したNK細胞活性、k)NK細胞の増加した動員、l)増加した好中球活性、m)増加したマクロファージ活性、及び/またはn)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数のうちの1つ以上を呈する調節された炎症性表現型を有する。一実施形態では、骨髄由来細胞は、マクロファージ、単球、循環骨髄由来単球、組織常駐マクロファージ、臨床状態に関連するマクロファージ、1型マクロファージ、M1マクロファージ、2型マクロファージ、M2マクロファージ、M2cマクロファージ、M2dマクロファージ、及び/または腫瘍関連マクロファージ(TAM)である。別の実施形態では、がんは、中皮腫、腎臓腎明細胞癌、膠芽腫、肺腺癌、肺扁平上皮癌、膵臓腺癌、乳房浸潤癌、急性骨髄性白血病、副腎皮質癌、膀胱尿路上皮癌、脳低悪性度神経膠腫、乳房浸潤癌、子宮頸部扁平上皮癌及び子宮頸部腺癌、胆管癌、結腸腺癌、食道癌、多形性膠芽腫、頭頸部扁平上皮癌、嫌色素性腎臓、腎臓腎明細胞癌、腎臓腎乳頭細胞癌、肝臓肝細胞癌、肺腺癌、肺扁平上皮癌、リンパ系新生物びまん性大細胞型B細胞リンパ腫、中皮腫、卵巣漿液性、嚢胞腺癌、膵臓腺癌、褐色細胞腫、傍神経節腫、前立腺腺癌、直腸腺癌、肉腫、皮膚皮膚黒色腫、胃腺癌、精巣胚細胞腫瘍、胸腺腫、甲状腺癌、子宮癌肉腫、子宮体子宮内膜癌、及びブドウ膜黒色腫からなる群から選択される。さらに別の実施形態では、骨髄由来細胞は、ヒト腫瘍モデル、がんの動物モデル、及び/またはチグリコール腹膜炎モデル内に含まれる。さらに別の実施形態では、対象は、哺乳動物である。別の実施形態では、哺乳動物は、がんを煩うヒトなどのヒトである。
特定の実施形態では、例えば、以下が提供される:
(項目1)
a)CCR2をコードする核酸分子にハイブリダイズする少なくとも1つのsiRNA分子、b)CSF1Rをコードする核酸分子にハイブリダイズする少なくとも1つのsiRNA分子、またはc)a)及びb)の組み合わせを含む、組成物。
(項目2)
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、配列番号6~配列番号67から選択される核酸配列を有するセンス鎖と、配列番号68~配列番号129から選択される核酸配列を有するアンチセンス鎖とを含む、項目1に記載の組成物。
(項目3)
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、配列番号130~配列番号248から選択される核酸配列を有するセンス鎖と、配列番号249~配列番号367から選択される核酸配列を有するアンチセンス鎖とを含む、項目1または2に記載の組成物。
(項目4)
CCR2またはCSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、少なくとも1つの修飾をさらに含む、項目1~3のいずれか1項に記載の組成物。
(項目5)
前記修飾が、前記核酸配列の糖部分への修飾、核酸塩基修飾、ヌクレオシド間リンカー修飾、人工ヌクレオチド、末端キャップ修飾、またはそれらの任意の組み合わせである、項目4に記載の組成物。
(項目6)
前記修飾が、前記少なくとも1つのsiRNA分子の前記センス鎖に位置する、項目4または5に記載の組成物。
(項目7)
前記修飾が、前記少なくとも1つのsiRNA分子の前記アンチセンス鎖に位置する、項目4または5に記載の組成物。
(項目8)
前記修飾が、前記少なくとも1つのsiRNA分子の前記センス及びアンチセンス鎖に位置する、項目4または5に記載の組成物。
(項目9)
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、配列番号368~配列番号486及び配列番号883~配列番号921から選択される修飾核酸配列を有するセンス鎖と、配列番号487~配列番号605及び配列番号922~配列番号960から選択される修飾核酸配列を有するアンチセンス鎖とを含む、項目4または5に記載の組成物。
(項目10)
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、配列番号606~配列番号743及び配列番号961~配列番号1001から選択される修飾核酸配列を有するセンス鎖と、配列番号744~配列番号881及び配列番号1002~配列番号1042から選択される修飾核酸配列を有するアンチセンス鎖とを含む、項目4、5、または9に記載の組成物。
(項目11)
a)CCR2をコードする核酸分子にハイブリダイズする少なくとも1つのsiRNA二本鎖、b)CSF1Rをコードする核酸分子にハイブリダイズする少なくとも1つのsiRNA二本鎖、またはc)a)及びb)の組み合わせを含む組成物であって、
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、配列番号6~配列番号67から選択される核酸配列、または配列番号606~配列番号743から選択される修飾核酸配列、または配列番号961~配列番号1001から選択される修飾バリアントを有するセンス鎖と、配列番号68~配列番号129から選択される核酸配列、または配列番号744~配列番号881から選択される修飾核酸配列、または配列番号1002~配列番号1042から選択される修飾バリアントを有するアンチセンス鎖とを含み、及び/または
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、配列番号130~配列番号248から選択される核酸配列、または配列番号368~配列番号486から選択される修飾核酸配列、または配列番号883~配列番号921から選択される修飾バリアントを有するセンス鎖と、配列番号249~配列番号367から選択される核酸配列、または配列番号487~配列番号605から選択される修飾核酸配列、または配列番号922~配列番号960から選択される修飾バリアントを有するアンチセンス鎖とを含む、前記組成物。
(項目12)
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-09048、XD-09050、XD-09098、XD-09117、XD-09127、XD-09043、XD-09045、XD-09060、XD-09062、XD-09086、XD-09094、XD-09095、XD-09107、XD-09112、XD-09113、XD-09115、XD-09121、XD-09138、XD-09143、もしくはXD-09149、またはそれらのバリアントである、項目11に記載の組成物。
(項目13)
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-09048、XD-09050、XD-09098、XD-09117、もしくはXD-09127、またはそれらのバリアントである、項目12に記載の組成物。
(項目14)
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-08944、XD-08947、XD-08988、XD-08993もしくはXD-08916、XD-08917、XD-08922、XD-08923、XD-08936、XD-08963、XD-08969、XD-08975、XD-08982、XD-08985、XD-08986、XD-08989、XD-09003、XD-09006、XD-09015、もしくはXD-09021、またはそれらのバリアントである、項目11~13のいずれか1項に記載の組成物。
(項目15)
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-08944、XD-08947、XD-08988、XD-08993、もしくはXD-08916、またはそれらのバリアントである、項目14に記載の組成物。
(項目16)
前記組成物が、脂質及び/またはリピドイドをさらに含む、項目1~15のいずれか1項に記載の組成物。
(項目17)
前記リピドイドが、式(VI)のものであって、
pが、1~3(境界値を含む)の整数であり、
mが、1~3(境界値を含む)の整数であり、
R
A
が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
R
F
が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
R
5
の各出現が独立して、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
ヘテロ脂肪族;置換もしくは非置換アリール;または置換もしくは非置換ヘテロアリールであり、
式中、R
A
、R
F
、R
Y
、及びR
Z
のうちの少なくとも1つが、
xの各出現が、1~10(境界値を含む)の整数であり、
yの各出現が、1~10(境界値を含む)の整数であり、
R
Y
の各出現が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
R
Z
の各出現が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C
1-20
ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
あるいはその薬学的に許容される塩である、項目16に記載の組成物。
(項目18)
pが、1である、項目17に記載の組成物。
(項目19)
mが、1である、項目17または18に記載の組成物。
(項目20)
p及びmの各々が、1である、項目17~19のいずれか1項に記載の組成物。
(項目21)
R
F
が、
(項目22)
R
A
が、
(項目23)
前記式(VI)の化合物が、以下の式のもの、
(項目24)
前記組成物が、脂質ナノ粒子の形態である、項目17~23のいずれか1項に記載の組成物。
(項目25)
前記脂質ナノ粒子が、約1.0モル%~約60.0モル%のC12-200を含む、項目24に記載の組成物。
(項目26)
前記脂質ナノ粒子が、1つ以上の共脂質をさらに含む、項目24または25に記載の組成物。
(項目27)
各共脂質が、ジステアロイルホスファチジルコリン(DSPC)、コレステロール、及びDMG-PEGから選択される、項目26に記載の組成物。
(項目28)
DSPCの濃度が、約1.0モル%~約20.0モル%である、項目27に記載の組成物。
(項目29)
コレステロールの濃度が、約10.0モル%~約50.0モル%である、項目27または28に記載の組成物。
(項目30)
DMG-PEGの濃度が、約0.1モル%~約5.0モル%である、項目27~29のいずれか1項に記載の組成物。
(項目31)
DSPCが、約1.0モル%~約20.0モル%の濃度で存在し、コレステロールが、約10.0モル%~約50.0モル%の濃度で存在し、DMG-PEGが、約0.1モル%~約5.0モル%の濃度で存在する、項目27~30のいずれか1項に記載の組成物。
(項目32)
C12-200、DSPC、コレステロール、及びDMG-PEGが、それぞれ50%:10%:38.5%:1.5%の比率で存在する、項目31に記載の組成物。
(項目33)
前記siRNA分子と比較して、LNPの前記脂質及びリピドドイドが、約20:1~約5:1の重量の比率で存在する、項目16~32のいずれか1項に記載の組成物。
(項目34)
前記siRNA分子と比較して、前記LNPの前記脂質及びリピドドイドが、9:1の重量の比率で存在する、項目33に記載の組成物。
(項目35)
前記組成物が、薬学的に許容される製剤中にある、項目1~34のいずれか1項に記載の組成物。
(項目36)
請求物1~35のいずれか1項に記載の少なくとも1つの組成物と接触した後に増加した炎症性表現型を有する骨髄由来細胞を生成する方法であって、前記骨髄由来細胞を有効量の前記少なくとも1つの組成物と接触させることを含む、前記方法。
(項目37)
増加した炎症性表現型を有する前記骨髄由来細胞が、前記少なくとも1つの組成物と接触した後に、以下:
a)表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
b)CD206、CD163、CD16、CD53、VSIG4、PSGL-1、TGFb、及び/またはIL-10の減少した発現、
c)IL-1β、TNF-α、IL-12、IL-18、GM-CSF、CCL3、CCL4、及びIL-23からなる群から選択される少なくとも1つのサイトカインもしくはケモカインの増加した分泌、
d)IL-1β、IL-6、及び/またはTNF-αの発現対IL-10の発現の増加した比率、
e)増加したCD8+細胞傷害性T細胞活性化、
f)CD8+細胞傷害性T細胞活性化の増加した動員、
g)増加したCD4+ヘルパーT細胞活性、
h)CD4+ヘルパーT細胞活性の増加した動員、
i)増加したNK細胞活性、
j)NK細胞の増加した動員、
k)増加した好中球活性、
l)増加したマクロファージ活性、及び/または
m)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈する、項目36に記載の方法。
(項目38)
前記少なくとも1つの組成物と接触した前記骨髄由来細胞が、細胞の集団内に含まれ、前記少なくとも1つの組成物が、前記細胞の集団内の1型及び/またはM1マクロファージの数を増加させ、及び/または2型及び/またはM2マクロファージの数を減少させる、項目36または37に記載の方法。
(項目39)
前記少なくとも1つの組成物と接触した前記骨髄由来細胞が、細胞の集団内に含まれ、前記少なくとも1つの組成物が、i)対ii)の比率を増加させ、前記細胞の集団内のi)が、1型及び/またはM1マクロファージであり、ii)が、2型及び/またはM2マクロファージである、項目36~38のいずれか1項に記載の方法。
(項目40)
前記骨髄由来細胞が、インビトロまたはエクスビボで接触する、項目36~39のいずれか1項に記載の方法。
(項目41)
前記骨髄由来細胞が、一次骨髄由来細胞である、項目40に記載の方法。
(項目42)
前記骨髄由来細胞が、前記少なくとも1つの組成物と接触する前に精製及び/または培養される、項目36~41のいずれか1項に記載の方法。
(項目43)
前記骨髄由来細胞が、インビボで接触する、項目36~39のいずれか1項に記載の方法。
(項目44)
前記骨髄由来細胞が、前記組成物の全身、腫瘍周囲、または腫瘍内投与によってインビボで接触する、項目43に記載の方法。
(項目45)
前記骨髄由来細胞が、それを必要とする対象において接触し、任意に、前記接触が、組織微小環境にある、項目43または44に記載の方法。
(項目46)
前記骨髄由来細胞を、少なくとも1つの追加の治療薬と接触させることをさらに含む、項目36~45のいずれか1項に記載の方法。
(項目47)
前記少なくとも1つの追加の治療薬が、CCL2のアンタゴニスト及び/またはCSF1のアンタゴニストである、項目46に記載の方法。
(項目48)
前記少なくとも1つの追加の治療薬が、前記炎症性表現型を調節する免疫療法剤を含み、任意に、前記免疫療法剤が、免疫チェックポイント阻害剤、免疫刺激アゴニスト、炎症剤、細胞、がんワクチン、及び/またはウイルスを含む、項目46または47のいずれか1項に記載の方法。
(項目49)
請求物1~35のいずれか1項に記載の少なくとも1つの組成物と接触した後に、対象における骨髄由来細胞の炎症性表現型を増加させる方法であって、前記骨髄由来細胞に接触する有効量の前記少なくとも1つの組成物を前記対象に投与することを含む、前記方法。
(項目50)
前記増加した炎症性表現型を有する前記骨髄由来細胞が、前記少なくとも1つの組成物と接触した後に、以下:
a)表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
b)CD206、CD163、CD16、CD53、VSIG4、PSGL-1、及び/またはIL-10の減少した発現、
c)IL-1β、TNF-α、IL-12、IL-18、及びIL-23からなる群から選択される少なくとも1つのサイトカインの増加した分泌、
d)IL-10の発現に対するIL-1β、IL-6、及び/またはTNF-αの発現の増加した比率、
e)増加したCD8+細胞傷害性T細胞活性化、
f)増加したCD4+ヘルパーT細胞活性、
g)増加したNK細胞活性、
h)増加した好中球活性、
i)増加したマクロファージ活性、及び/または
j)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈する、項目49に記載の方法。
(項目51)
前記少なくとも1つの組成物が、1型及び/またはM1マクロファージの数を増加させ、2型及び/またはM2マクロファージの数を減少させ、及び/またはi)対ii)の比率を増加させ、前記対象におけるi)が、1型及び/またはM1マクロファージであり、ii)が、2型及び/またはM2マクロファージである、項目49または50に記載の方法。
(項目52)
前記対象における細胞傷害性CD8+T細胞の数及び/または活性が、前記少なくとも1つの組成物の投与後に増加される、項目49~51のいずれか1項に記載の方法。
(項目53)
前記少なくとも1つの組成物が、全身、腫瘍周囲、または腫瘍内に投与される、項目49~52のいずれか1項に記載の方法。
(項目54)
前記少なくとも1つの組成物が、組織微小環境で前記骨髄由来細胞と接触する、項目49~53のいずれか1項に記載の方法。
(項目55)
前記骨髄由来細胞を、少なくとも1つの追加の治療薬と接触させることをさらに含む、項目49~54のいずれか1項に記載の方法。
(項目56)
前記少なくとも1つの追加の治療薬が、CCL2のアンタゴニスト及び/またはCSF1のアンタゴニストである、項目55に記載の方法。
(項目57)
前記少なくとも1つの追加の治療薬が、前記炎症性表現型を調節する免疫療法剤を含み、任意に、前記免疫療法剤が、免疫チェックポイント阻害剤、免疫刺激アゴニスト、炎症剤、細胞、がんワクチン、及び/またはウイルスを含む、項目55または56に記載の方法。
(項目58)
前記免疫チェックポイントが、PD-1、PD-L1、PD-L2、及びCTLA-4からなる群から選択される、項目57に記載の方法。
(項目59)
前記免疫チェックポイントが、PD-1である、項目58に記載の方法。
(項目60)
前記少なくとも1つの追加の治療薬またはレジメンが、前記少なくとも1つの組成物の前、それと同時、またはその後に投与される、項目55~59のいずれか1項に記載の方法。
(項目61)
対象におけるがん細胞を細胞傷害性CD8+T細胞媒介性殺傷及び/または免疫チェックポイント療法に対して増感させる方法であって、前記対象において骨髄由来細胞を接触させるために、項目1~35のいずれか1項に記載の治療有効量の少なくとも1つの組成物を前記対象に投与することを含む、前記方法。
(項目62)
前記少なくとも1つの組成物が、全身、腫瘍周囲、または腫瘍内に投与される、項目61に記載の方法。
(項目63)
有効量の少なくとも1つの追加の治療薬を前記対象に投与することによって、前記対象における前記がんを治療することをさらに含む、項目61または62に記載の方法。
(項目64)
前記少なくとも1つの追加の治療薬が、CCL2のアンタゴニスト及び/またはCSF1のアンタゴニストである、項目63に記載の方法。
(項目65)
前記少なくとも1つの追加の治療薬が、前記骨髄由来細胞の前記炎症性表現型を調節する免疫療法剤を含み、任意に、前記免疫療法剤が、免疫チェックポイント阻害剤、免疫刺激アゴニスト、炎症剤、細胞、がんワクチン、及び/またはウイルスを含む、項目63または64に記載の方法。
(項目66)
前記免疫チェックポイントが、PD-1、PD-L1、PD-L2、及びCTLA-4からなる群から選択される、項目65に記載の方法。
(項目67)
前記免疫チェックポイントが、PD-1である、項目66に記載の方法。
(項目68)
前記少なくとも1つの追加の治療薬またはレジメンが、前記少なくとも1つの組成物の前、それと同時、またはその後に投与される、項目67に記載の方法。
(項目69)
前記少なくとも1つの組成物が、前記がんにおける増殖細胞の数を低減し、及び/または前記がん細胞を含む腫瘍の体積もしくはサイズを低減する、項目61~68のいずれか1項に記載の方法。
(項目70)
前記少なくとも1つの組成物が、前記がん細胞を含む腫瘍に浸潤するCD8+T細胞の量及び/または活性を増加させる、項目61~69のいずれか1項に記載の方法。
(項目71)
前記少なくとも1つの組成物が、a)前記がん細胞を含む腫瘍に浸潤するM1マクロファージの量及び/または活性を増加させる、及び/またはb)前記がん細胞を含む腫瘍に浸潤するM2マクロファージの量及び/または活性を減少させる、項目61~70のいずれか1項に記載の方法。
(項目72)
前記少なくとも1つの組成物と接触した前記骨髄由来細胞が、以下:
a)単球及び/またはマクロファージによるCCR2及び/またはCSF1R受容体の減少した発現、
b)単球及び/またはマクロファージによる、表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
c)単球及び/またはマクロファージによる、CD206、CD163、CD16、CD53、VSIG4、PSGL-1、TGFb、及び/またはIL-10の減少した発現、
d)単球及び/またはマクロファージによる、IL-1β、TNF-α、IL-12、IL-18、GM-CSF、CCL3、CCL4、及びIL-2からなる群から選択される少なくとも1つのサイトカインもしくはケモカインの増加した分泌、
e)単球及び/またはマクロファージによる、IL-1β、IL-6、及び/またはTNF-αの発現対IL-10の発現の増加した比率、
f)増加したCD8+細胞傷害性T細胞活性化、
g)CD8+細胞傷害性T細胞活性化の増加した動員、
h)増加したCD4+ヘルパーT細胞活性、
i)CD4+ヘルパーT細胞活性の増加した動員、
j)増加したNK細胞活性、
k)NK細胞の増加した動員、
l)増加した好中球活性、
m)増加したマクロファージ活性、及び/または
n)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈する調節された炎症性表現型を有する、項目36~71のいずれか1項に記載の方法。
(項目73)
前記骨髄由来細胞が、マクロファージ、単球、循環骨髄由来単球、組織常駐マクロファージ、臨床状態に関連するマクロファージ、1型マクロファージ、M1マクロファージ、2型マクロファージ、M2マクロファージ、M2cマクロファージ、M2dマクロファージ、及び/または腫瘍関連マクロファージ(TAM)である、項目36~72のいずれか1項に記載の方法。
(項目74)
前記がんが、中皮腫、腎臓腎明細胞癌、膠芽腫、肺腺癌、肺扁平上皮癌、膵臓腺癌、乳房浸潤癌、急性骨髄性白血病、副腎皮質癌、膀胱尿路上皮癌、脳低悪性度神経膠腫、乳房浸潤癌、子宮頸部扁平上皮癌及び子宮頸部腺癌、胆管癌、結腸腺癌、食道癌、多形性膠芽腫、頭頸部扁平上皮癌、嫌色素性腎臓、腎臓腎明細胞癌、腎臓腎乳頭細胞癌、肝臓肝細胞癌、肺腺癌、肺扁平上皮癌、リンパ系新生物びまん性大細胞型B細胞リンパ腫、中皮腫、卵巣漿液性、嚢胞腺癌、膵臓腺癌、褐色細胞腫、傍神経節腫、前立腺腺癌、直腸腺癌、肉腫、皮膚皮膚黒色腫、胃腺癌、精巣胚細胞腫瘍、胸腺腫、甲状腺癌、子宮癌肉腫、子宮体子宮内膜癌、及びブドウ膜黒色腫からなる群から選択される、項目36~73のいずれか1項に記載の方法。
(項目75)
前記骨髄由来細胞が、ヒト腫瘍モデル、がんの動物モデル、及び/またはチグリコール腹膜炎モデル内に含まれる、項目36~74のいずれか1項に記載の方法。
(項目76)
前記対象が、哺乳動物である、項目36~75のいずれか1項に記載の方法。
(項目77)
前記哺乳動物が、ヒトである、項目76に記載の方法。
(項目78)
前記ヒトが、がんに罹患している、項目77に記載の方法。
In one embodiment, bone marrow-derived cells contacted with at least one composition are characterized by: a) decreased expression of CCR2 and/or CSF1R receptors by monocytes and/or macrophages, b) monocytes and/or macrophages surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin-1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF, and/or tumor necrosis factor alpha (TNF c) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1, TGFb, and/or IL-10 by monocytes and/or macrophages, d) monocytes and/or or increased secretion by macrophages of at least one cytokine or chemokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, GM-CSF, CCL3, CCL4, and IL-2, e f) increased CD8+ cytotoxic T cell activation; increased recruitment of CD8+ cytotoxic T cell activation, h) increased CD4+ helper T cell activity, i) increased recruitment of CD4+ helper T cell activity, j) increased NK cell activity, k) increased NK cells recruitment, l) increased neutrophil activity, m) increased macrophage activity, and/or n) increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy. have a modulated inflammatory phenotype exhibiting one or more of In one embodiment, the bone marrow-derived cells are macrophages, monocytes, circulating bone marrow-derived monocytes, tissue-resident macrophages, macrophages associated with clinical conditions, type 1 macrophages, M1 macrophages, type 2 macrophages, M2 macrophages, M2c macrophages, M2d macrophages, and/or tumor-associated macrophages (TAM). In another embodiment, the cancer is mesothelioma, renal clear cell carcinoma, glioblastoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, breast invasive carcinoma, acute myeloid leukemia, adrenocortical carcinoma, Bladder urothelial carcinoma, brain low-grade glioma, breast invasive carcinoma, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct cancer, colon adenocarcinoma, esophageal cancer, glioblastoma multiforme, head and neck Squamous cell carcinoma, chromophobe kidney, renal clear cell carcinoma, renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, lymphoid neoplasm, diffuse large B-cell lymphoma, mesothelium tumor, ovarian serous, cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostatic adenocarcinoma, rectal adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, thyroid selected from the group consisting of carcinoma, uterine carcinosarcoma, endometrial carcinoma, and uveal melanoma. In yet another embodiment, bone marrow-derived cells are included in human tumor models, animal models of cancer, and/or tigkyl peritonitis models. In yet another embodiment, the subject is a mammal. In another embodiment, the mammal is a human, such as a human with cancer.
In certain embodiments, for example, the following are provided:
(Item 1)
A composition comprising a) at least one siRNA molecule that hybridizes to a nucleic acid molecule encoding CCR2, b) at least one siRNA molecule that hybridizes to a nucleic acid molecule encoding CSF1R, or c) a combination of a) and b) thing.
(Item 2)
said at least one siRNA molecule that hybridizes to said nucleic acid molecule encoding CCR2 has a sense strand having a nucleic acid sequence selected from SEQ ID NO: 6-67 and a nucleic acid selected from SEQ ID NO: 68-129 The composition of item 1, comprising an antisense strand having a sequence.
(Item 3)
said at least one siRNA molecule hybridizing to said nucleic acid molecule encoding CSF1R has a sense strand having a nucleic acid sequence selected from SEQ ID NOs: 130-248 and a nucleic acid selected from SEQ ID NOs: 249-367 3. A composition according to item 1 or 2, comprising an antisense strand having the sequence.
(Item 4)
4. The composition of any one of items 1-3, wherein said at least one siRNA molecule hybridizing to said nucleic acid molecule encoding CCR2 or CSF1R further comprises at least one modification.
(Item 5)
5. The composition of item 4, wherein said modification is a modification to the sugar moiety of said nucleic acid sequence, a nucleobase modification, an internucleoside linker modification, an artificial nucleotide, an end cap modification, or any combination thereof.
(Item 6)
6. The composition of items 4 or 5, wherein said modification is located in said sense strand of said at least one siRNA molecule.
(Item 7)
6. The composition of items 4 or 5, wherein said modification is located in said antisense strand of said at least one siRNA molecule.
(Item 8)
6. The composition of items 4 or 5, wherein said modifications are located in said sense and antisense strands of said at least one siRNA molecule.
(Item 9)
said at least one siRNA molecule hybridizing to said nucleic acid molecule encoding CCR2 has a sense strand having a modified nucleic acid sequence selected from SEQ ID NOs:368-486 and SEQ ID NOs:883-921; and SEQ ID NO:487. and an antisense strand having a modified nucleic acid sequence selected from SEQ ID NO:605 and SEQ ID NO:922-SEQ ID NO:960.
(Item 10)
a sense strand, wherein said at least one siRNA molecule that hybridizes to said nucleic acid molecule encoding CCR2 has a modified nucleic acid sequence selected from SEQ ID NOs:606-743 and SEQ ID NOs:961-1001; and an antisense strand having a modified nucleic acid sequence selected from SEQ ID NO:881 and SEQ ID NO:1002-SEQ ID NO:1042.
(Item 11)
a) at least one siRNA duplex that hybridizes to a nucleic acid molecule encoding CCR2, b) at least one siRNA duplex that hybridizes to a nucleic acid molecule encoding CSF1R, or c) a combination of a) and b) A composition comprising
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is a nucleic acid sequence selected from SEQ ID NO: 6 to SEQ ID NO: 67, or a modified nucleic acid sequence selected from SEQ ID NO: 606 to SEQ ID NO: 743 , or a sense strand having a modified variant selected from SEQ ID NO:961 to SEQ ID NO:1001 and a nucleic acid sequence selected from SEQ ID NO:68 to SEQ ID NO:129, or a modified nucleic acid sequence selected from SEQ ID NO:744 to SEQ ID NO:881 , or an antisense strand having a modified variant selected from SEQ ID NO: 1002 to SEQ ID NO: 1042, and/or
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CSF1R is a nucleic acid sequence selected from SEQ ID NO: 130-SEQ ID NO: 248, or a modified nucleic acid sequence selected from SEQ ID NO: 368-486 , or a sense strand having a modified variant selected from SEQ ID NO:883 to SEQ ID NO:921 and a nucleic acid sequence selected from SEQ ID NO:249 to SEQ ID NO:367, or a modified nucleic acid sequence selected from SEQ ID NO:487 to SEQ ID NO:605 , or an antisense strand having a modified variant selected from SEQ ID NO:922-SEQ ID NO:960.
(Item 12)
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is double stranded XD-09048, XD-09050, XD-09098, XD-09117, XD-09127, XD-09043, XD- 09045, XD-09060, XD-09062, XD-09086, XD-09094, XD-09095, XD-09107, XD-09112, XD-09113, XD-09115, XD-09121, XD-09138, XD-09143, or XD-09149, or a variant thereof.
(Item 13)
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is double stranded XD-09048, XD-09050, XD-09098, XD-09117, or XD-09127, or variants thereof 13. The composition of item 12, wherein
(Item 14)
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CSF1R is double stranded XD-08944, XD-08947, XD-08988, XD-08993 or XD-08916, XD-08917, XD- 08922, XD-08923, XD-08936, XD-08963, XD-08969, XD-08975, XD-08982, XD-08985, XD-08986, XD-08989, XD-09003, XD-09006, XD-09015, or XD-09021, or a variant thereof, according to any one of items 11-13.
(Item 15)
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CSF1R is double stranded XD-08944, XD-08947, XD-08988, XD-08993, or XD-08916, or variants thereof 15. The composition of item 14, wherein
(Item 16)
16. Composition according to any one of items 1 to 15, wherein said composition further comprises lipids and/or lipidoids.
(Item 17)
wherein said lipidoid is of formula (VI)
p is an integer from 1 to 3 (including boundary values);
m is an integer from 1 to 3 (including boundary values),
R A is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; or unsubstituted aryl; substituted or unsubstituted heteroaryl;
R F is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; or unsubstituted aryl; substituted or unsubstituted heteroaryl;
substituted or unsubstituted , cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1- 20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
wherein at least one of R A , R F , R Y and R Z is
each occurrence of x is an integer from 1 to 10 (inclusive);
each occurrence of y is an integer from 1 to 10 (inclusive);
substituted or unsubstituted , cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic family; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;
substituted or unsubstituted , cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic family; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;
or a composition according to item 16, which is a pharmaceutically acceptable salt thereof.
(Item 18)
18. The composition of item 17, wherein p is 1.
(Item 19)
19. The composition of items 17 or 18, wherein m is 1.
(Item 20)
20. The composition according to any one of items 17-19, wherein each of p and m is 1.
(Item 21)
RF is _
(Item 22)
RA is _
(Item 23)
wherein the compound of formula (VI) is of the formula:
(Item 24)
24. The composition of any one of items 17-23, wherein the composition is in the form of lipid nanoparticles.
(Item 25)
25. The composition of item 24, wherein said lipid nanoparticles comprise from about 1.0 mol % to about 60.0 mol % C12-200.
(Item 26)
26. The composition of item 24 or 25, wherein said lipid nanoparticles further comprise one or more co-lipids.
(Item 27)
27. The composition of item 26, wherein each co-lipid is selected from distearoylphosphatidylcholine (DSPC), cholesterol, and DMG-PEG.
(Item 28)
28. The composition of item 27, wherein the concentration of DSPC is from about 1.0 mol % to about 20.0 mol %.
(Item 29)
29. The composition of items 27 or 28, wherein the concentration of cholesterol is from about 10.0 mol % to about 50.0 mol %.
(Item 30)
30. The composition of any one of items 27-29, wherein the concentration of DMG-PEG is from about 0.1 mol% to about 5.0 mol%.
(Item 31)
DSPC is present at a concentration of about 1.0 mol % to about 20.0 mol %, cholesterol is present at a concentration of about 10.0 mol % to about 50.0 mol %, DMG-PEG is present at a concentration of about 31. The composition of any one of items 27-30, present in a concentration from 0.1 mol % to about 5.0 mol %.
(Item 32)
32. The composition of item 31, wherein C12-200, DSPC, cholesterol, and DMG-PEG are present in ratios of 50%:10%:38.5%:1.5%, respectively.
(Item 33)
33. The composition of any one of items 16-32, wherein said lipid of LNP and lipidoidoid are present in a weight ratio of about 20:1 to about 5:1 relative to said siRNA molecule.
(Item 34)
34. The composition of item 33, wherein said lipid and lipidoidoid of said LNP are present in a weight ratio of 9:1 compared to said siRNA molecule.
(Item 35)
35. The composition of any one of items 1-34, wherein said composition is in a pharmaceutically acceptable formulation.
(Item 36)
36. A method of producing bone marrow-derived cells having an increased inflammatory phenotype after contact with at least one composition of any one of claims 1-35, wherein said bone marrow-derived cells are combined with an effective amount of said The above method, comprising contacting with at least one composition.
(Item 37)
After the bone marrow-derived cells with an increased inflammatory phenotype are contacted with the at least one composition,
a) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF, and/or tumor necrosis factor alpha increased expression of (TNF-α),
b) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1, TGFb, and/or IL-10;
c) increased secretion of at least one cytokine or chemokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, GM-CSF, CCL3, CCL4, and IL-23;
d) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression;
e) increased CD8+ cytotoxic T cell activation;
f) increased recruitment of CD8+ cytotoxic T cell activation;
g) increased CD4+ helper T cell activity;
h) increased recruitment of CD4+ helper T cell activity;
i) increased NK cell activity,
j) increased recruitment of NK cells,
k) increased neutrophil activity,
l) increased macrophage activity, and/or
m) The method of item 36, exhibiting one or more of increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy.
(Item 38)
said bone marrow-derived cells contacted with said at least one composition are contained within a population of cells, said at least one composition increasing the number of type 1 and/or M1 macrophages within said population of cells; and/or reducing the number of type 2 and/or M2 macrophages.
(Item 39)
said bone marrow-derived cells contacted with said at least one composition are contained within a population of cells, wherein said at least one composition increases the ratio of i) to ii) and i) within said population of cells; are type 1 and/or M1 macrophages and ii) are type 2 and/or M2 macrophages.
(Item 40)
40. The method of any one of items 36-39, wherein said bone marrow-derived cells are contacted in vitro or ex vivo.
(Item 41)
41. The method of item 40, wherein said bone marrow-derived cells are primary bone marrow-derived cells.
(Item 42)
42. The method of any one of items 36-41, wherein said bone marrow-derived cells are purified and/or cultured prior to contact with said at least one composition.
(Item 43)
40. The method of any one of items 36-39, wherein said bone marrow-derived cells are contacted in vivo.
(Item 44)
44. The method of item 43, wherein said bone marrow-derived cells are contacted in vivo by systemic, peritumoral, or intratumoral administration of said composition.
(Item 45)
45. The method of paragraphs 43 or 44, wherein said bone marrow-derived cells are contacted in a subject in need thereof, optionally said contact is in a tissue microenvironment.
(Item 46)
46. The method of any one of items 36-45, further comprising contacting said bone marrow-derived cells with at least one additional therapeutic agent.
(Item 47)
47. The method of item 46, wherein said at least one additional therapeutic agent is an antagonist of CCL2 and/or an antagonist of CSF1.
(Item 48)
said at least one additional therapeutic agent comprises an immunotherapeutic agent that modulates said inflammatory phenotype, optionally wherein said immunotherapeutic agent is an immune checkpoint inhibitor, an immunostimulatory agonist, an inflammatory agent, a cell, a cancer 48. A method according to any one of items 46 or 47, comprising a vaccine and/or virus.
(Item 49)
36. A method of increasing the inflammatory phenotype of bone marrow-derived cells in a subject following contact with at least one composition of any one of claims 1-35, comprising an effective amount contacting said bone marrow-derived cells. administering to said subject said at least one composition of
(Item 50)
After the bone marrow-derived cells with the increased inflammatory phenotype are contacted with the at least one composition, the following:
a) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF, and/or tumor necrosis factor alpha increased expression of (TNF-α),
b) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1 and/or IL-10;
c) increased secretion of at least one cytokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, and IL-23;
d) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression;
e) increased CD8+ cytotoxic T cell activation;
f) increased CD4+ helper T cell activity;
g) increased NK cell activity,
h) increased neutrophil activity,
i) increased macrophage activity and/or
j) The method of item 49, exhibiting one or more of increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy.
(Item 51)
wherein said at least one composition increases the number of type 1 and/or M1 macrophages, decreases the number of type 2 and/or M2 macrophages, and/or increases the ratio of i) to ii), wherein said subject 51. A method according to item 49 or 50, wherein i) in is type 1 and/or M1 macrophages and ii) is type 2 and/or M2 macrophages.
(Item 52)
52. The method of any one of items 49-51, wherein the number and/or activity of cytotoxic CD8+ T cells in said subject is increased after administration of said at least one composition.
(Item 53)
53. The method of any one of items 49-52, wherein said at least one composition is administered systemically, peritumorally, or intratumorally.
(Item 54)
54. The method of any one of items 49-53, wherein said at least one composition contacts said bone marrow-derived cells in a tissue microenvironment.
(Item 55)
55. The method of any one of items 49-54, further comprising contacting said bone marrow-derived cells with at least one additional therapeutic agent.
(Item 56)
56. The method of item 55, wherein said at least one additional therapeutic agent is an antagonist of CCL2 and/or an antagonist of CSF1.
(Item 57)
said at least one additional therapeutic agent comprises an immunotherapeutic agent that modulates said inflammatory phenotype, optionally wherein said immunotherapeutic agent is an immune checkpoint inhibitor, an immunostimulatory agonist, an inflammatory agent, a cell, a cancer 57. Method according to item 55 or 56, comprising a vaccine and/or virus.
(Item 58)
58. The method of item 57, wherein said immune checkpoint is selected from the group consisting of PD-1, PD-L1, PD-L2, and CTLA-4.
(Item 59)
59. The method of item 58, wherein said immune checkpoint is PD-1.
(Item 60)
60. The method of any one of items 55-59, wherein said at least one additional therapeutic agent or regimen is administered before, concurrently with, or after said at least one composition.
(Item 61)
36. A method of sensitizing cancer cells in a subject to cytotoxic CD8+ T cell-mediated killing and/or immune checkpoint therapy, comprising any of items 1-35 for contacting bone marrow-derived cells in said subject. 3. The method, comprising administering to the subject a therapeutically effective amount of at least one composition of claim 1.
(Item 62)
62. The method of item 61, wherein the at least one composition is administered systemically, peritumorally, or intratumorally.
(Item 63)
63. The method of item 61 or 62, further comprising treating said cancer in said subject by administering an effective amount of at least one additional therapeutic agent to said subject.
(Item 64)
64. The method of item 63, wherein said at least one additional therapeutic agent is an antagonist of CCL2 and/or an antagonist of CSF1.
(Item 65)
said at least one additional therapeutic agent comprises an immunotherapeutic agent that modulates said inflammatory phenotype of said bone marrow-derived cells, optionally said immunotherapeutic agent is an immune checkpoint inhibitor, an immunostimulatory agonist, an inflammatory agent , cells, cancer vaccines, and/or viruses.
(Item 66)
66. The method of item 65, wherein said immune checkpoint is selected from the group consisting of PD-1, PD-L1, PD-L2, and CTLA-4.
(Item 67)
67. The method of item 66, wherein said immune checkpoint is PD-1.
(Item 68)
68. The method of item 67, wherein said at least one additional therapeutic agent or regimen is administered before, concurrently with, or after said at least one composition.
(Item 69)
69. Any one of items 61 to 68, wherein said at least one composition reduces the number of proliferating cells in said cancer and/or reduces the volume or size of a tumor comprising said cancer cells. Method.
(Item 70)
70. The method of any one of items 61-69, wherein said at least one composition increases the amount and/or activity of CD8+ T cells infiltrating a tumor comprising said cancer cells.
(Item 71)
said at least one composition a) increases the amount and/or activity of M1 macrophages infiltrating a tumor containing said cancer cells; and/or b) increases the amount and/or activity of M2 macrophages infiltrating said tumor containing cancer cells 71. A method according to any one of items 61-70, wherein the amount and/or activity is reduced.
(Item 72)
The bone marrow-derived cells contacted with the at least one composition are:
a) decreased expression of CCR2 and/or CSF1R receptors by monocytes and/or macrophages,
b) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF by monocytes and/or macrophages , and/or increased expression of tumor necrosis factor alpha (TNF-α),
c) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1, TGFb and/or IL-10 by monocytes and/or macrophages;
d) at least one cytokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, GM-CSF, CCL3, CCL4 and IL-2 by monocytes and/or macrophages or increased secretion of chemokines,
e) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression by monocytes and/or macrophages;
f) increased CD8+ cytotoxic T cell activation;
g) increased recruitment of CD8+ cytotoxic T cell activation;
h) increased CD4+ helper T cell activity;
i) increased recruitment of CD4+ helper T cell activity;
j) increased NK cell activity,
k) increased recruitment of NK cells,
l) increased neutrophil activity,
m) increased macrophage activity, and/or
n) having a modulated inflammatory phenotype exhibiting one or more of increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy, item 36. 71. The method of any one of paragraphs 1-71.
(Item 73)
said bone marrow-derived cells are macrophages, monocytes, circulating bone marrow-derived monocytes, tissue-resident macrophages, clinically associated macrophages, type 1 macrophages, M1 macrophages, type 2 macrophages, M2 macrophages, M2c macrophages, M2d macrophages, and/or or tumor-associated macrophages (TAM).
(Item 74)
The cancer is mesothelioma, renal clear cell carcinoma, glioblastoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, breast invasive carcinoma, acute myelogenous leukemia, adrenocortical carcinoma, bladder urothelial carcinoma , brain low-grade glioma, breast invasive carcinoma, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct cancer, colon adenocarcinoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, Pigmented kidney, renal clear cell carcinoma, renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, lymphoid neoplasm, diffuse large B-cell lymphoma, mesothelioma, ovarian serous , cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostatic adenocarcinoma, rectal adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, thyroid cancer, uterine carcinosarcoma 74. The method of any one of items 36-73, selected from the group consisting of uterine endometrial cancer, and uveal melanoma.
(Item 75)
75. The method of any one of items 36-74, wherein said bone marrow-derived cells are contained within a human tumor model, an animal model of cancer, and/or a tiglycol peritonitis model.
(Item 76)
76. The method of any one of items 36-75, wherein the subject is a mammal.
(Item 77)
77. The method of item 76, wherein said mammal is a human.
(Item 78)
78. The method of item 77, wherein said human has cancer.
Claims (24)
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA分子が、配列番号130~配列番号248から選択される核酸配列を有するセンス鎖と、配列番号249~配列番号367から選択される核酸配列を有するアンチセンス鎖とを含む、請求項1に記載の組成物。 said at least one siRNA molecule hybridizing to said nucleic acid molecule encoding CCR2 has a sense strand having a nucleic acid sequence selected from SEQ ID NOs: 6-67 and a nucleic acid selected from SEQ ID NOs: 68-129 an antisense strand having a sequence ; and/or
said at least one siRNA molecule hybridizing to said nucleic acid molecule encoding CSF1R has a sense strand having a nucleic acid sequence selected from SEQ ID NOs: 130-248 and a nucleic acid selected from SEQ ID NOs: 249-367 2. The composition of claim 1 , comprising an antisense strand having the sequence .
前記修飾が、前記少なくとも1つのsiRNA分子の前記アンチセンス鎖に位置する;または
前記修飾が、前記少なくとも1つのsiRNA分子の前記センス及びアンチセンス鎖に位置する、請求項3に記載の組成物。 said modification is located on said sense strand of said at least one siRNA molecule ;
said modification is located on said antisense strand of said at least one siRNA molecule; or
4. The composition of claim 3 , wherein said modifications are located on said sense and antisense strands of said at least one siRNA molecule .
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、配列番号6~配列番号67から選択される核酸配列、または配列番号606~配列番号743から選択される修飾核酸配列、または配列番号961~配列番号1001から選択される修飾バリアントを有するセンス鎖と、配列番号68~配列番号129から選択される核酸配列、または配列番号744~配列番号881から選択される修飾核酸配列、または配列番号1002~配列番号1042から選択される修飾バリアントを有するアンチセンス鎖とを含み、及び/または
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、配列番号130~配列番号248から選択される核酸配列、または配列番号368~配列番号486から選択される修飾核酸配列、または配列番号883~配列番号921から選択される修飾バリアントを有するセンス鎖と、配列番号249~配列番号367から選択される核酸配列、または配列番号487~配列番号605から選択される修飾核酸配列、または配列番号922~配列番号960から選択される修飾バリアントを有するアンチセンス鎖とを含む、前記組成物。 a) at least one siRNA duplex that hybridizes to a nucleic acid molecule encoding CCR2, b) at least one siRNA duplex that hybridizes to a nucleic acid molecule encoding CSF1R, or c) a combination of a) and b) A composition comprising
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is a nucleic acid sequence selected from SEQ ID NO: 6 to SEQ ID NO: 67, or a modified nucleic acid sequence selected from SEQ ID NO: 606 to SEQ ID NO: 743 , or a sense strand having a modified variant selected from SEQ ID NO:961 to SEQ ID NO:1001 and a nucleic acid sequence selected from SEQ ID NO:68 to SEQ ID NO:129, or a modified nucleic acid sequence selected from SEQ ID NO:744 to SEQ ID NO:881 or an antisense strand having a modified variant selected from SEQ ID NO: 1002 to SEQ ID NO: 1042, and/or a sense strand having a nucleic acid sequence selected from SEQ ID NO: 130 to SEQ ID NO: 248, or a modified nucleic acid sequence selected from SEQ ID NO: 368 to SEQ ID NO: 486, or a modified variant selected from SEQ ID NO: 883 to SEQ ID NO: 921; 249 to SEQ ID NO:367, or a modified nucleic acid sequence selected from SEQ ID NO:487 to SEQ ID NO:605, or an antisense strand having a modified variant selected from SEQ ID NO:922 to SEQ ID NO:960 , said composition.
CCR2をコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-09048、XD-09050、XD-09098、XD-09117、もしくはXD-09127、またはそれらのバリアントである、ならびに/あるいは
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-08944、XD-08947、XD-08988、XD-08993もしくはXD-08916、XD-08917、XD-08922、XD-08923、XD-08936、XD-08963、XD-08969、XD-08975、XD-08982、XD-08985、XD-08986、XD-08989、XD-09003、XD-09006、XD-09015、もしくはXD-09021、またはそれらのバリアントであり、任意に、
CSF1Rをコードする前記核酸分子にハイブリダイズする前記少なくとも1つのsiRNA二本鎖が、二本鎖XD-08944、XD-08947、XD-08988、XD-08993、もしくはXD-08916、またはそれらのバリアントである、請求項7に記載の組成物。 said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is double stranded XD-09048, XD-09050, XD-09098, XD-09117, XD-09127, XD-09043, XD- 09045, XD-09060, XD-09062, XD-09086, XD-09094, XD-09095, XD-09107, XD-09112, XD-09113, XD-09115, XD-09121, XD-09138, XD-09143, or XD-09149, or variants thereof , optionally
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CCR2 is double stranded XD-09048, XD-09050, XD-09098, XD-09117, or XD-09127, or variants thereof is and/or
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CSF1R is double stranded XD-08944, XD-08947, XD-08988, XD-08993 or XD-08916, XD-08917, XD- 08922, XD-08923, XD-08936, XD-08963, XD-08969, XD-08975, XD-08982, XD-08985, XD-08986, XD-08989, XD-09003, XD-09006, XD-09015, or XD-09021, or variants thereof, optionally
said at least one siRNA duplex that hybridizes to said nucleic acid molecule encoding CSF1R is double stranded XD-08944, XD-08947, XD-08988, XD-08993, or XD-08916, or variants thereof 8. The composition of claim 7 , wherein a
pが、1~3(境界値を含む)の整数であり、
mが、1~3(境界値を含む)の整数であり、
RAが、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
RFが、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
R5の各出現が独立して、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20ヘテロ脂肪族;置換もしくは非置換アリール;または置換もしくは非置換ヘテロアリールであり、
式中、RA、RF、RY、及びRZのうちの少なくとも1つが、
xの各出現が、1~10(境界値を含む)の整数であり、
yの各出現が、1~10(境界値を含む)の整数であり、
RYの各出現が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
RZの各出現が、水素;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20脂肪族;置換もしくは非置換、環状もしくは非環状、分岐もしくは非分岐C1-20ヘテロ脂肪族;置換もしくは非置換アリール;置換もしくは非置換ヘテロアリール;
あるいはその薬学的に許容される塩である、請求項9に記載の組成物。 wherein said lipidoid is of formula (VI)
p is an integer from 1 to 3 (including boundary values);
m is an integer from 1 to 3 (including boundary values),
R A is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; or unsubstituted aryl; substituted or unsubstituted heteroaryl;
R F is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic; or unsubstituted aryl; substituted or unsubstituted heteroaryl;
substituted or unsubstituted, cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1- 20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
wherein at least one of R A , R F , R Y and R Z is
each occurrence of x is an integer from 1 to 10 (inclusive);
each occurrence of y is an integer from 1 to 10 (inclusive);
substituted or unsubstituted, cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic family; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;
substituted or unsubstituted, cyclic or acyclic , branched or unbranched C 1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C 1-20 heteroaliphatic family; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;
10. The composition according to claim 9 , which is a pharmaceutically acceptable salt thereof.
mが、1である;
p及びmの各々が、1である;
R F が、
R A が、
m is 1;
each of p and m is 1;
RF is _
RA is _
各共脂質が、ジステアロイルホスファチジルコリン(DSPC)、コレステロール、及びDMG-PEGから選択され、任意に、
DSPCの濃度が、約1.0モル%~約20.0モル%であり、
さらに任意に、コレステロールの濃度が、約10.0モル%~約50.0モル%であり;
DMG-PEGの濃度が、約0.1モル%~約5.0モル%であり;ならびに/あるいは
DSPCが、約1.0モル%~約20.0モル%の濃度で存在し、コレステロールが、約10.0モル%~約50.0モル%の濃度で存在し、DMG-PEGが、約0.1モル%~約5.0モル%の濃度で存在し、任意に、
C12-200、DSPC、コレステロール、及びDMG-PEGが、それぞれ50%:10%:38.5%:1.5%の比率で存在する、請求項13に記載の組成物。 said lipid nanoparticles further comprising one or more co-lipids , optionally
each co-lipid is selected from distearoylphosphatidylcholine (DSPC), cholesterol, and DMG-PEG; optionally
the concentration of DSPC is from about 1.0 mol % to about 20.0 mol %;
Further optionally, the concentration of cholesterol is from about 10.0 mol % to about 50.0 mol %;
the concentration of DMG-PEG is from about 0.1 mol % to about 5.0 mol %; and/or
DSPC is present at a concentration of about 1.0 mol % to about 20.0 mol %, cholesterol is present at a concentration of about 10.0 mol % to about 50.0 mol %, DMG-PEG is present at a concentration of about present in a concentration from 0.1 mol % to about 5.0 mol %, optionally
14. The composition of claim 13 , wherein C12-200, DSPC, cholesterol, and DMG-PEG are present in a ratio of 50%:10%:38.5%:1.5%, respectively .
前記siRNA分子と比較して、前記LNPの前記脂質及びリピドドイドが、9:1の重量の比率で存在する、請求項9~14のいずれか1項に記載の組成物。 said lipid and lipidoidoid of LNP are present in a weight ratio of from about 20:1 to about 5:1 compared to said siRNA molecule;
15. The composition of any one of claims 9-14 , wherein said lipid and lipidoidoid of said LNP are present in a weight ratio of 9:1 compared to said siRNA molecule .
a)表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
b)CD206、CD163、CD16、CD53、VSIG4、PSGL-1、TGFb、及び/またはIL-10の減少した発現、
c)IL-1β、TNF-α、IL-12、IL-18、GM-CSF、CCL3、CCL4、及びIL-23からなる群から選択される少なくとも1つのサイトカインもしくはケモカインの増加した分泌、
d)IL-1β、IL-6、及び/またはTNF-αの発現対IL-10の発現の増加した比率、
e)増加したCD8+細胞傷害性T細胞活性化、
f)CD8+細胞傷害性T細胞活性化の増加した動員、
g)増加したCD4+ヘルパーT細胞活性、
h)CD4+ヘルパーT細胞活性の増加した動員、
i)増加したNK細胞活性、
j)NK細胞の増加した動員、
k)増加した好中球活性、
l)増加したマクロファージ活性、及び/または
m)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈し、任意に
前記少なくとも1つの組成物と接触した前記骨髄由来細胞が、細胞の集団内に含まれ、前記少なくとも1つの組成物が、前記細胞の集団内の1型及び/またはM1マクロファージの数を増加させ、及び/または2型及び/またはM2マクロファージの数を減少させる;ならびに/あるいは
前記少なくとも1つの組成物と接触した前記骨髄由来細胞が、細胞の集団内に含まれ、前記少なくとも1つの組成物が、i)対ii)の比率を増加させ、前記細胞の集団内のi)が、1型及び/またはM1マクロファージであり、ii)が、2型及び/またはM2マクロファージである;ならびに/あるいは
前記骨髄由来細胞が、一次骨髄由来細胞である;ならびに/あるいは
前記骨髄由来細胞が、前記少なくとも1つの組成物と接触する前に精製及び/または培養される、請求項17に記載の方法。 After the bone marrow-derived cells with an increased inflammatory phenotype are contacted with the at least one composition,
a) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF, and/or tumor necrosis factor alpha increased expression of (TNF-α),
b) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1, TGFb, and/or IL-10;
c) increased secretion of at least one cytokine or chemokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, GM-CSF, CCL3, CCL4, and IL-23;
d) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression;
e) increased CD8+ cytotoxic T cell activation;
f) increased recruitment of CD8+ cytotoxic T cell activation;
g) increased CD4+ helper T cell activity;
h) increased recruitment of CD4+ helper T cell activity;
i) increased NK cell activity,
j) increased recruitment of NK cells,
k) increased neutrophil activity,
exhibiting one or more of l) increased macrophage activity, and/or m) increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy; arbitrarily
said bone marrow-derived cells contacted with said at least one composition are contained within a population of cells, said at least one composition increasing the number of type 1 and/or M1 macrophages within said population of cells; and/or reduce the number of type 2 and/or M2 macrophages; and/or
said bone marrow-derived cells contacted with said at least one composition are contained within a population of cells, wherein said at least one composition increases the ratio of i) to ii) and i) within said population of cells; are type 1 and/or M1 macrophages and ii) are type 2 and/or M2 macrophages; and/or
said bone marrow-derived cells are primary bone marrow-derived cells; and/or
18. The method of claim 17 , wherein said bone marrow-derived cells are purified and/or cultured prior to contacting said at least one composition .
a)表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
b)CD206、CD163、CD16、CD53、VSIG4、PSGL-1、及び/またはIL-10の減少した発現、
c)IL-1β、TNF-α、IL-12、IL-18、及びIL-23からなる群から選択される少なくとも1つのサイトカインの増加した分泌、
d)IL-10の発現に対するIL-1β、IL-6、及び/またはTNF-αの発現の増加した比率、
e)増加したCD8+細胞傷害性T細胞活性化、
f)増加したCD4+ヘルパーT細胞活性、
g)増加したNK細胞活性、
h)増加した好中球活性、
i)増加したマクロファージ活性、及び/または
j)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈し、任意に、
前記少なくとも1つの組成物が、1型及び/またはM1マクロファージの数を増加させ、2型及び/またはM2マクロファージの数を減少させ、及び/またはi)対ii)の比率を増加させ、前記対象におけるi)が、1型及び/またはM1マクロファージであり、ii)が、2型及び/またはM2マクロファージである;ならびに/あるいは
前記対象における細胞傷害性CD8+T細胞の数及び/または活性が、前記少なくとも1つの組成物の投与後に増加される、請求項18に記載の方法における使用のための少なくとも1つの組成物。 After the bone marrow-derived cells with the increased inflammatory phenotype are contacted with the at least one composition, the following:
a) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF, and/or tumor necrosis factor alpha increased expression of (TNF-α),
b) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1 and/or IL-10;
c) increased secretion of at least one cytokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, and IL-23;
d) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression;
e) increased CD8+ cytotoxic T cell activation,
f) increased CD4+ helper T cell activity;
g) increased NK cell activity,
h) increased neutrophil activity,
exhibiting one or more of i) increased macrophage activity, and/or j) increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy; optionally,
wherein said at least one composition increases the number of type 1 and/or M1 macrophages, decreases the number of type 2 and/or M2 macrophages, and/or increases the ratio of i) to ii), wherein said subject i) in is type 1 and/or M1 macrophages and ii) is type 2 and/or M2 macrophages; and/or
19. At least one composition for use in the method of claim 18 , wherein the number and/or activity of cytotoxic CD8+ T cells in said subject is increased following administration of said at least one composition.
前記少なくとも1つの組成物が、組織微小環境で前記骨髄由来細胞と接触することを特徴とする;ならびに/あるいは
前記骨髄由来細胞を、少なくとも1つの追加の治療薬と接触させることをさらに含み、任意に、
前記少なくとも1つの追加の治療薬が、CCL2のアンタゴニスト及び/またはCSF1のアンタゴニストであり、さらに任意に、
前記少なくとも1つの追加の治療薬が、前記炎症性表現型を調節する免疫療法剤を含み、任意に、前記免疫療法剤が、免疫チェックポイント阻害剤、免疫刺激アゴニスト、炎症剤、細胞、がんワクチン、及び/またはウイルスを含み、任意に、
前記免疫チェックポイントが、PD-1、PD-L1、PD-L2、及びCTLA-4からなる群から選択され、さらに任意に、
前記免疫チェックポイントが、PD-1である;ならびに/あるいは
前記少なくとも1つの追加の治療薬またはレジメンが、前記少なくとも1つの組成物の前、それと同時、またはその後に投与されることを特徴とする、請求項18または20のいずれか1項に記載の方法における使用のための少なくとも1つの組成物。 wherein said at least one composition is administered systemically, peritumorally, or intratumorally ;
wherein said at least one composition contacts said bone marrow-derived cells in a tissue microenvironment; and/or
further comprising contacting said bone marrow-derived cells with at least one additional therapeutic agent;
said at least one additional therapeutic agent is an antagonist of CCL2 and/or an antagonist of CSF1, and optionally
said at least one additional therapeutic agent comprises an immunotherapeutic agent that modulates said inflammatory phenotype, optionally wherein said immunotherapeutic agent is an immune checkpoint inhibitor, an immunostimulatory agonist, an inflammatory agent, a cell, a cancer including vaccines and/or viruses, optionally
said immune checkpoint is selected from the group consisting of PD-1, PD-L1, PD-L2, and CTLA-4, and optionally,
said immune checkpoint is PD-1; and/or
21. The method of any one of claims 18 or 20 , wherein said at least one additional therapeutic agent or regimen is administered prior to, concurrently with, or after said at least one composition. at least one composition for use in
有効量の少なくとも1つの追加の治療薬を前記対象に投与することによって、前記対象における前記がんを治療することをさらに含み、任意に、
前記少なくとも1つの追加の治療薬が、CCL2のアンタゴニスト及び/またはCSF1のアンタゴニストであり、さらに任意に、
前記少なくとも1つの追加の治療薬が、前記骨髄由来細胞の前記炎症性表現型を調節する免疫療法剤を含み、任意に、前記免疫療法剤が、免疫チェックポイント阻害剤、免疫刺激アゴニスト、炎症剤、細胞、がんワクチン、及び/またはウイルスを含み、任意に、
前記免疫チェックポイントが、PD-1、PD-L1、PD-L2、及びCTLA-4からなる群から選択され、さらに任意に、
前記免疫チェックポイントが、PD-1であり、任意に、
前記少なくとも1つの追加の治療薬またはレジメンが、前記少なくとも1つの組成物の前、それと同時、またはその後に投与されることを特徴とする;ならびに/あるいは
前記少なくとも1つの組成物が、前記がんにおける増殖細胞の数を低減し、及び/または前記がん細胞を含む腫瘍の体積もしくはサイズを低減する;ならびに/あるいは
前記少なくとも1つの組成物が、前記がん細胞を含む腫瘍に浸潤するCD8+T細胞の量及び/または活性を増加させる;ならびに/あるいは
前記少なくとも1つの組成物が、a)前記がん細胞を含む腫瘍に浸潤するM1マクロファージの量及び/または活性を増加させる、及び/またはb)前記がん細胞を含む腫瘍に浸潤するM2マクロファージの量及び/または活性を減少させる、請求項22に記載の方法における使用のための組成物。 wherein said at least one composition is administered systemically, peritumorally, or intratumorally ;
further comprising treating said cancer in said subject by administering to said subject an effective amount of at least one additional therapeutic agent;
said at least one additional therapeutic agent is an antagonist of CCL2 and/or an antagonist of CSF1, and optionally
said at least one additional therapeutic agent comprises an immunotherapeutic agent that modulates said inflammatory phenotype of said bone marrow-derived cells, optionally said immunotherapeutic agent is an immune checkpoint inhibitor, an immunostimulatory agonist, an inflammatory agent , cells, cancer vaccines, and/or viruses, optionally
said immune checkpoint is selected from the group consisting of PD-1, PD-L1, PD-L2, and CTLA-4, and optionally,
said immune checkpoint is PD-1, optionally
wherein said at least one additional therapeutic agent or regimen is administered before, concurrently with, or after said at least one composition; and/or
said at least one composition reduces the number of proliferating cells in said cancer and/or reduces the volume or size of a tumor comprising said cancer cells; and/or
said at least one composition increases the amount and/or activity of CD8+ T cells infiltrating a tumor containing said cancer cells; and/or
said at least one composition a) increases the amount and/or activity of M1 macrophages infiltrating a tumor containing said cancer cells; and/or b) increases the amount and/or activity of M2 macrophages infiltrating said tumor containing cancer cells 23. A composition for use in the method of claim 22 , wherein the amount and/or activity is reduced .
a)単球及び/またはマクロファージによるCCR2及び/またはCSF1R受容体の減少した発現、
b)単球及び/またはマクロファージによる、表面抗原分類80(CD80)、CD86、MHCII、MHCI、インターロイキン1-ベータ(IL-1β)、IL-6、CCL3、CCL4、CXCL10、CXCL9、GM-CSF、及び/または腫瘍壊死因子アルファ(TNF-α)の増加した発現、
c)単球及び/またはマクロファージによる、CD206、CD163、CD16、CD53、VSIG4、PSGL-1、TGFb、及び/またはIL-10の減少した発現、
d)単球及び/またはマクロファージによる、IL-1β、TNF-α、IL-12、IL-18、GM-CSF、CCL3、CCL4、及びIL-2からなる群から選択される少なくとも1つのサイトカインもしくはケモカインの増加した分泌、
e)単球及び/またはマクロファージによる、IL-1β、IL-6、及び/またはTNF-αの発現対IL-10の発現の増加した比率、
f)増加したCD8+細胞傷害性T細胞活性化、
g)CD8+細胞傷害性T細胞活性化の増加した動員、
h)増加したCD4+ヘルパーT細胞活性、
i)CD4+ヘルパーT細胞活性の増加した動員、
j)増加したNK細胞活性、
k)NK細胞の増加した動員、
l)増加した好中球活性、
m)増加したマクロファージ活性、及び/または
n)顕微鏡法で評価した場合の、増加した紡錘形の形態、外観の平坦性、及び/または樹状突起の数、のうちの1つ以上を呈する調節された炎症性表現型を有する;ならびに/あるいは
前記骨髄由来細胞が、マクロファージ、単球、循環骨髄由来単球、組織常駐マクロファージ、臨床状態に関連するマクロファージ、1型マクロファージ、M1マクロファージ、2型マクロファージ、M2マクロファージ、M2cマクロファージ、M2dマクロファージ、及び/または腫瘍関連マクロファージ(TAM)である;
前記がんが、中皮腫、腎臓腎明細胞癌、膠芽腫、肺腺癌、肺扁平上皮癌、膵臓腺癌、乳房浸潤癌、急性骨髄性白血病、副腎皮質癌、膀胱尿路上皮癌、脳低悪性度神経膠腫、乳房浸潤癌、子宮頸部扁平上皮癌及び子宮頸部腺癌、胆管癌、結腸腺癌、食道癌、多形性膠芽腫、頭頸部扁平上皮癌、嫌色素性腎臓、腎臓腎明細胞癌、腎臓腎乳頭細胞癌、肝臓肝細胞癌、肺腺癌、肺扁平上皮癌、リンパ系新生物びまん性大細胞型B細胞リンパ腫、中皮腫、卵巣漿液性、嚢胞腺癌、膵臓腺癌、褐色細胞腫、傍神経節腫、前立腺腺癌、直腸腺癌、肉腫、皮膚皮膚黒色腫、胃腺癌、精巣胚細胞腫瘍、胸腺腫、甲状腺癌、子宮癌肉腫、子宮体子宮内膜癌、及びブドウ膜黒色腫からなる群から選択される;
前記骨髄由来細胞が、ヒト腫瘍モデル、がんの動物モデル、及び/またはチグリコール腹膜炎モデル内に含まれる;ならびに/あるいは
前記対象が、哺乳動物であり、任意に、
前記哺乳動物が、ヒトであり、さらに任意に、
前記ヒトが、がんに罹患している、請求項17もしくは19に記載の方法、請求項18、20もしくは21に記載の方法における使用のための少なくとも1つの組成物、または請求項22もしくは23に記載の方法における使用のための組成物。 The bone marrow-derived cells contacted with the at least one composition are:
a) decreased expression of CCR2 and/or CSF1R receptors by monocytes and/or macrophages,
b) surface antigen class 80 (CD80), CD86, MHCII, MHCI, interleukin 1-beta (IL-1β), IL-6, CCL3, CCL4, CXCL10, CXCL9, GM-CSF by monocytes and/or macrophages , and/or increased expression of tumor necrosis factor alpha (TNF-α),
c) decreased expression of CD206, CD163, CD16, CD53, VSIG4, PSGL-1, TGFb and/or IL-10 by monocytes and/or macrophages;
d) at least one cytokine selected from the group consisting of IL-1β, TNF-α, IL-12, IL-18, GM-CSF, CCL3, CCL4 and IL-2 by monocytes and/or macrophages or increased secretion of chemokines,
e) an increased ratio of IL-1β, IL-6, and/or TNF-α expression to IL-10 expression by monocytes and/or macrophages;
f) increased CD8+ cytotoxic T cell activation;
g) increased recruitment of CD8+ cytotoxic T cell activation;
h) increased CD4+ helper T cell activity;
i) increased recruitment of CD4+ helper T cell activity;
j) increased NK cell activity,
k) increased recruitment of NK cells,
l) increased neutrophil activity,
m) increased macrophage activity, and/or n) increased spindle morphology, flatness in appearance, and/or number of dendrites as assessed by microscopy. have an inflammatory phenotype ; and/or
said bone marrow-derived cells are macrophages, monocytes, circulating bone marrow-derived monocytes, tissue-resident macrophages, clinically associated macrophages, type 1 macrophages, M1 macrophages, type 2 macrophages, M2 macrophages, M2c macrophages, M2d macrophages, and/or or tumor-associated macrophages (TAM);
The cancer is mesothelioma, renal clear cell carcinoma, glioblastoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, breast invasive carcinoma, acute myelogenous leukemia, adrenocortical carcinoma, bladder urothelial carcinoma , brain low-grade glioma, breast invasive carcinoma, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct cancer, colon adenocarcinoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, Pigmented kidney, renal clear cell carcinoma, renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, lymphoid neoplasm, diffuse large B-cell lymphoma, mesothelioma, ovarian serous , cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostatic adenocarcinoma, rectal adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, thyroid cancer, uterine carcinosarcoma , endometrial cancer, and uveal melanoma;
said bone marrow-derived cells are contained within a human tumor model, an animal model of cancer, and/or a Tiglycol peritonitis model; and/or
said subject is a mammal, optionally
said mammal is a human, further optionally
24. The method of claim 17 or 19 , at least one composition for use in the method of claim 18, 20 or 21, or claim 22 or 23 , wherein said human is suffering from cancer. A composition for use in the method described in .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862716671P | 2018-08-09 | 2018-08-09 | |
US62/716,671 | 2018-08-09 | ||
PCT/US2019/045841 WO2020033791A1 (en) | 2018-08-09 | 2019-08-09 | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534101A JP2021534101A (en) | 2021-12-09 |
JPWO2020033791A5 true JPWO2020033791A5 (en) | 2022-08-17 |
Family
ID=69413677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506632A Pending JP2021534101A (en) | 2018-08-09 | 2019-08-09 | Oligonucleotide compositions for targeting CCR2 and CSF1R and their use |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210317461A1 (en) |
EP (1) | EP3833762A4 (en) |
JP (1) | JP2021534101A (en) |
WO (1) | WO2020033791A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11642629B2 (en) * | 2020-03-20 | 2023-05-09 | Saudi Arabian Oil Company | Multi-layer composite gas separation membranes, methods for preparation, and use |
US20220025436A1 (en) * | 2020-07-21 | 2022-01-27 | Rutgers, The State University Of New Jersey | Method and Kit For CCR2 Expression Profiling And Disease Stratification |
DE112022000079T5 (en) * | 2021-04-01 | 2023-06-15 | Hayk Davtyan | Genetic modification of mammalian cells to confer resistance to CSF1R antagonists |
Family Cites Families (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8748A (en) | 1852-02-17 | Improvement in weighing-machines | ||
US7569A (en) | 1850-08-13 | Improvement in ship-ventilators | ||
US575A (en) | 1838-01-20 | Benjamin iapham | ||
US815A (en) | 1838-06-30 | Improved cooking-stove for summer | ||
US5047533A (en) | 1983-05-24 | 1991-09-10 | Sri International | Acyclic purine phosphonate nucleotide analogs |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
DE3650699T2 (en) | 1985-03-15 | 1999-04-15 | Antivirals Inc | Immunoassay for polynucleotide and methods |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
JPH03503894A (en) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | Oligonucleotide N-alkylphosphoramidate |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
EP0745833A3 (en) | 1991-07-25 | 1998-09-23 | The Whitaker Corporation | Liquid level sensor |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
WO1994018987A1 (en) | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Drug composition containing nucleic acid copolymer |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
CA2200952C (en) | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
SE9600820D0 (en) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US6008334A (en) | 1996-07-24 | 1999-12-28 | The Board Of Regents Of The University Of Oklahoma | Base-protected nucleotide analogs with protected thiol groups |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6267987B1 (en) | 1997-12-12 | 2001-07-31 | Samyang Corporation | Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
US6517869B1 (en) | 1997-12-12 | 2003-02-11 | Expression Genetics, Inc. | Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
BR9911062A (en) | 1998-05-20 | 2001-02-06 | Expression Genetics Inc | Poly-l-lysine polymer gene vehicle grafted by hepatocyte targeting polyethylene glycol |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
HUP0102152A3 (en) | 1998-05-26 | 2002-04-29 | Icn Pharmaceuticals Inc Costa | Nucleosid and oligo nucleotid analogues having bicyclic sugar derivative |
MXPA01000271A (en) | 1998-07-13 | 2002-10-17 | Expression Genetics Inc | Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier. |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
CN1361829A (en) | 1999-03-18 | 2002-07-31 | 埃克西库恩公司 | Detection of mutations in genes by specific LNA primers |
EP1194035B1 (en) | 1999-06-29 | 2007-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
PT1210428E (en) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, a receptor for b7-4, and uses therefor |
US6936704B1 (en) | 1999-08-23 | 2005-08-30 | Dana-Farber Cancer Institute, Inc. | Nucleic acids encoding costimulatory molecule B7-4 |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2003520828A (en) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート,エルエルシー | Antibodies to CTLA4 (CD152), conjugates containing the same, and uses thereof |
US20020042370A1 (en) | 2000-04-14 | 2002-04-11 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CCR2 function |
GB0016258D0 (en) | 2000-07-03 | 2000-08-23 | Amersham Pharm Biotech Uk Ltd | Base analogues |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
DE60119562T2 (en) | 2000-10-04 | 2007-05-10 | Santaris Pharma A/S | IMPROVED SYNTHESIS OF PURIN-BLOCKED NUCLEIC ACID ANALOGUE |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
WO2003020739A2 (en) | 2001-09-04 | 2003-03-13 | Exiqon A/S | Novel lna compositions and uses thereof |
US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
AU2003272369A1 (en) | 2002-09-13 | 2004-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
CN101899114A (en) | 2002-12-23 | 2010-12-01 | 惠氏公司 | Anti-PD-1 antibody and uses thereof |
WO2004069809A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
CA2515892C (en) | 2003-02-14 | 2012-10-23 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
CA2529488A1 (en) | 2003-06-16 | 2004-12-23 | Kyushu Tlo Company, Limited | Method for producing human-derived immunocompetent cells |
EP1631311A4 (en) | 2003-12-10 | 2007-04-11 | Millennium Pharm Inc | Humanized anti-ccr2 antibodies and methods of use |
US7927873B2 (en) | 2003-12-19 | 2011-04-19 | University Of Cincinnati | Polyamides for nucleic acid delivery |
WO2005101002A1 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 2 (ccr2) |
AU2005329255B2 (en) | 2004-04-15 | 2010-09-30 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
EP1753758B1 (en) | 2004-05-26 | 2009-03-11 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
MX2007000036A (en) | 2004-06-25 | 2007-05-18 | Johnson & Johnson | Quaternary salt ccr2 antagonists. |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
CA2603853C (en) | 2005-04-01 | 2013-11-19 | Intezyne Technologies, Incorporated | Polymeric micelles for drug delivery |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US7368439B2 (en) | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
WO2007013085A1 (en) | 2005-07-26 | 2007-02-01 | Hetero Drugs Limited | Novel process for acyclic phosphonate nucleotide analogs |
KR20080083187A (en) | 2006-01-05 | 2008-09-16 | 노바르티스아게 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
WO2007082305A2 (en) | 2006-01-12 | 2007-07-19 | Massachusetts Institute Of Technology | Biodegradable elastomers |
US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
US20140200259A1 (en) * | 2006-02-23 | 2014-07-17 | Novartis Ag | RNAi-MEDIATED INHIBITION OF SELECT RECEPTOR TYROSINE KINASES FOR TREATMENT OF PATHOLOGIC OCULAR NEOVASCULARIZATION-RELATED CONDITIONS |
WO2007125173A2 (en) | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
WO2007147026A2 (en) | 2006-06-15 | 2007-12-21 | Centocor, Inc. | Ccr2 antagonists for chronic organ transplantation rejection |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
DE602007012261D1 (en) | 2006-07-14 | 2011-03-10 | Chemocentryx Inc | TRIAZOLYL-PYRIDYL-BENZOLSULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS |
MX2009003548A (en) | 2006-10-03 | 2009-04-15 | Alnylam Pharmaceuticals Inc | Lipid containing formulations. |
WO2008073558A2 (en) | 2006-10-05 | 2008-06-19 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
WO2008109238A1 (en) | 2007-03-02 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted cyclopentyl piperidine ccr2 antagonists |
US7678894B2 (en) | 2007-05-18 | 2010-03-16 | Helicos Biosciences Corporation | Nucleotide analogs |
MX2009012568A (en) | 2007-05-22 | 2009-12-08 | Mdrna Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes. |
WO2009009740A1 (en) | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
PT2644594T (en) | 2007-09-28 | 2017-11-20 | Pfizer | Cancer cell targeting using nanoparticles |
WO2009075344A1 (en) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
WO2010005740A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
WO2010005725A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
JP2012501965A (en) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | Drug-loaded polymer nanoparticles and methods for producing and using the same |
JP5530430B2 (en) | 2008-06-23 | 2014-06-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Piperidylacrylamide antagonist of CCR2 |
CN102239180B (en) | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | Antibodies to CCR2 |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
MX2011004859A (en) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Aminoalcohol lipidoids and uses thereof. |
US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
EP3238738B1 (en) | 2008-11-10 | 2020-09-23 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
KR20110097915A (en) | 2008-12-03 | 2011-08-31 | 마리나 바이오테크, 인크. | Usirna complexes |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
WO2010101870A1 (en) | 2009-03-03 | 2010-09-10 | St. Jude Children's Research Hospital | Compositions and methods for generating interleukin-35-induced regulatory t cells |
EP2414322B1 (en) | 2009-03-20 | 2022-09-14 | Egen, Inc. | Polyamine derivatives |
US8287910B2 (en) | 2009-04-30 | 2012-10-16 | Intezyne Technologies, Inc. | Polymeric micelles for polynucleotide encapsulation |
US20110020388A1 (en) | 2009-05-27 | 2011-01-27 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
SI3431076T1 (en) | 2009-06-10 | 2022-04-29 | Arbutus Biopharma Corporation | Improved lipid formulation |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
KR101151415B1 (en) | 2009-07-10 | 2012-06-01 | 양지화학 주식회사 | Piperazinylethyl 3-Aminopyrrolidine Derivatives as CCR2 Antagonists |
WO2011019679A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Ccr2 inhibitors for treating conditions of the eye |
US9181295B2 (en) | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
BR112012003462A2 (en) | 2009-08-24 | 2016-02-23 | Ascepion Pharmaceuticals Inc | "compound, pharmaceutical composition, and method for treating a patient having a protein kinase mediated condition." |
US8828975B2 (en) | 2009-09-25 | 2014-09-09 | National Cheng-Kung University | Phosphate-containing nanoparticle delivery vehicle |
US8471004B2 (en) | 2009-10-07 | 2013-06-25 | Hoffman-La Roche Inc. | Bicyclic compounds |
WO2011043913A2 (en) | 2009-10-08 | 2011-04-14 | Merck Sharp & Dohme Corp. | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
CN102753327B (en) | 2009-11-02 | 2015-01-14 | 马斯特模具(2007)有限公司 | A database for injection mold and integration with an injection molding machine and auxiliary components |
EP2509634B1 (en) | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
JP5965844B2 (en) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | Therapeutic polymer nanoparticle compositions having high glass transition temperature or high molecular weight copolymers |
US8429390B2 (en) | 2009-12-24 | 2013-04-23 | Insyde Software Corp. | Method for performing quick boot and general boot at bios stage |
US9670487B2 (en) | 2010-01-22 | 2017-06-06 | Sirna Therapeutics, Inc. | Cationic lipids for oligonucleotide delivery |
CA2787598A1 (en) | 2010-01-24 | 2012-06-21 | Novartis Ag | Irradiated biodegradable polymer microparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
EP2562255A4 (en) | 2010-04-21 | 2013-10-30 | Riken | Nucleic acid base analog with quenching characteristics and fluorescence and application thereof |
WO2011133876A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
WO2011140249A2 (en) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
WO2011140294A1 (en) | 2010-05-07 | 2011-11-10 | Swapsol Corp. | Method and apparatus for eliminating pollutants from a gas stream |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
TW201211027A (en) | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
KR101743280B1 (en) | 2010-06-17 | 2017-06-02 | 얀센 파마슈티카 엔.브이. | Cyclohexyl-azetidinyl antagonists of ccr2 |
US20120000768A1 (en) | 2010-07-02 | 2012-01-05 | Primestar Solar, Inc. | Methods for sputtering a resistive transparent buffer thin film for use in cadmium telluride based photovoltaic devices |
DE102010032758B4 (en) | 2010-07-29 | 2012-02-23 | Fujitsu Technology Solutions Intellectual Property Gmbh | Computer system, method of programming a real time clock and computer program product |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
SG186706A1 (en) | 2010-07-30 | 2013-02-28 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP2609344B1 (en) | 2010-08-24 | 2014-05-07 | GKN Driveline International GmbH | Boot for joints, especially for constant velocity joints, with a transition area |
CN103167866B (en) | 2010-09-20 | 2015-09-23 | 瑟纳治疗公司 | For the novel low molecular weight amount cation lipid of oligonucleotide delivery |
AU2011307277A1 (en) | 2010-09-30 | 2013-03-07 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | Therapeutic nanoparticles with high molecular weight copolymers |
EP2635681B8 (en) | 2010-11-05 | 2017-10-04 | Miragen Therapeutics, Inc. | Base modified oligonucleotides |
WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
DE102011082231A1 (en) | 2011-01-12 | 2012-07-12 | Robert Bosch Gmbh | Ignition coil, especially for small engines |
WO2012109121A1 (en) | 2011-02-07 | 2012-08-16 | Purdue Research Foundation | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
US20140005165A1 (en) | 2011-03-17 | 2014-01-02 | Anilkumar G. Nair | Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists |
WO2012125663A2 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists |
WO2012125662A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Indole derivatives useful as ccr2 antagonists |
WO2012135010A2 (en) | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
EA027410B1 (en) | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Tolerogenic nanocarriers to reduce cytotoxic t lymphocyte responses |
WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
DK2723360T3 (en) | 2011-06-27 | 2017-08-28 | Université Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
KR102066297B1 (en) | 2011-10-14 | 2020-01-14 | 암비트 바이오사이언시즈 코포레이션 | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
WO2013062134A1 (en) | 2011-10-25 | 2013-05-02 | Fumihiko Ishikawa | Method for producing immune-system humanized mouse |
EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
CA2856742A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
EP2807182A1 (en) | 2012-01-23 | 2014-12-03 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Stabilized peptide helices for inhibiting dimerization of chemokine c motif receptor 2 (ccr2) |
US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
US9315579B2 (en) | 2012-06-22 | 2016-04-19 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CCR2 |
CN105358551A (en) | 2012-07-19 | 2016-02-24 | 詹森药业有限公司 | Octahydro-cyclopentapyrrolyl antagonists of CCR2 |
JP6298818B2 (en) | 2012-08-17 | 2018-03-20 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Water-soluble nitric oxide releasing polyglucosamine and their use |
WO2014124329A1 (en) | 2013-02-08 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
CA2906132C (en) | 2013-03-15 | 2021-01-05 | Stemcell Technologies Inc. | Compositions and methods for obtaining enriched mesenchymal stem cell cultures |
CN105873902B (en) | 2013-11-18 | 2019-03-08 | 阿克丘勒斯治疗公司 | Ionizable cation lipid for RNA delivery |
US9365610B2 (en) | 2013-11-18 | 2016-06-14 | Arcturus Therapeutics, Inc. | Asymmetric ionizable cationic lipid for RNA delivery |
DE102013112789B4 (en) | 2013-11-19 | 2017-09-28 | Phoenix Contact Gmbh & Co. Kg | Transport auxiliary device and arrangement with a strand formed from electromechanical components and a corresponding transport auxiliary device |
CN106460025A (en) | 2014-03-25 | 2017-02-22 | 阿克丘勒斯治疗公司 | UNA oligomers having reduced off-target effects in gene silencing |
US10975153B2 (en) | 2014-06-23 | 2021-04-13 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
CN104168449B (en) | 2014-07-15 | 2017-06-20 | 阔地教育科技有限公司 | A kind of tracing area method for handover control and system |
KR20170096187A (en) | 2014-12-22 | 2017-08-23 | 파이브 프라임 테라퓨틱스, 인크. | Anti-csf1r antibodies for treating pvns |
BR112017020952A2 (en) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | cancer treatment method, composition and use of composition |
AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
EP3216861A1 (en) | 2016-03-11 | 2017-09-13 | Fropharm GmbH | Immunoregulatory cells and methods for their production |
-
2019
- 2019-08-09 EP EP19846282.2A patent/EP3833762A4/en active Pending
- 2019-08-09 WO PCT/US2019/045841 patent/WO2020033791A1/en unknown
- 2019-08-09 US US17/265,699 patent/US20210317461A1/en active Pending
- 2019-08-09 JP JP2021506632A patent/JP2021534101A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109476718B (en) | Combination of MRNA encoding immunomodulatory polypeptides and uses thereof | |
US20230193258A1 (en) | Methods and compositions for the treatment of cancer or other diseases | |
US8946175B1 (en) | Stabilized immunomodulatory oligonucleotides | |
TWI541024B (en) | Antisense nucleic acid | |
JP2017163994A (en) | Antisense nucleic acids | |
EP2873674A1 (en) | Chiral nucleic acid adjuvant | |
CA2962849A1 (en) | Ebolavirus and marburgvirus vaccines | |
EP3269811A1 (en) | Nucleic acid having adjuvant activity and use thereof | |
WO2017068791A1 (en) | Nucleic acid complex having at least one bulge structure | |
EP3532617B1 (en) | Antisense oligonucleotides | |
JP2021520402A (en) | Skin permeable transmitter containing nucleic acid complex and its use | |
CN106467915B (en) | SiRNA and its application and the method for inhibiting plk1 gene expression | |
JPWO2020033791A5 (en) | ||
TW201038278A (en) | Rnai molecule for thymidylate synthase and use thereof | |
CA2846074A1 (en) | Compositions and methods for treatment of metastatic cancer | |
CN106999573B (en) | Adjuvant compositions | |
US20110071210A1 (en) | Methods and compositions for the treatment of cancer or other diseases | |
AU2021236879A1 (en) | A mixture of mRNA to enhance the potency of dendritic cells | |
JP2023554111A (en) | Nucleic acid construct capable of simultaneous gene expression and suppression | |
JP2024028895A (en) | Oligonucleotide molecules and their application in tumor therapy | |
WO2022235975A2 (en) | Sirna constructs for inhibiting gene expression in targeted cancer cells | |
JP2020193160A (en) | Drug carrier for pulmonary delivery and pulmonary disease therapeutic drug containing the same | |
JP2015500808A (en) | Treatment of B-cell lymphoma | |
JPWO2020102558A5 (en) | ||
RU2013114741A (en) | UNIVERSAL CANCER-SPECIFIC PROMOTORS FOR EXPRESSION OF TRANSGENES IN TUMOR CELLS |